Overview

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

Status:
NOT_YET_RECRUITING
Trial end date:
2032-08-16
Target enrollment:
Participant gender:
Summary
To determine the recommended Phase IIa dose (RP2D) of the triplet combination. To determine the safety and efficacy of the combination at the RP2D.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Ipilimumab
Nivolumab
relatlimab